GQG Partners’s Bristol-Myers Squibb BMY Stock Holding History

GQG Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.55M	Buy	96,264 +49,903	+108%	+$2.87M	0.01%	76
2026 Q1	$2.81M	Buy	+46,361	New	+$2.7M	﹤0.01%	64
2025 Q3	–	Sell	-3,025,192	Closed	-$140M	–	96
2025 Q2	$140M	Sell	3,025,192 -8,998,262	-75%	-$442M	0.2%	53
2025 Q1	$733M	Buy	12,023,454 +11,970,598	+22,648%	+$698M	1.17%	29
2024 Q4	$2.99M	Buy	+52,856	New	+$2.95M	﹤0.01%	81
2023 Q2	–	Sell	-42,232	Closed	-$2.93M	–	72
2023 Q1	$2.93M	Sell	42,232 -471,183	-92%	-$33.2M	0.01%	67
2022 Q4	$36.9M	Buy	513,415 +51,365	+11%	+$3.87M	0.1%	50
2022 Q3	$32.9M	Sell	462,050 -1,015,421	-69%	-$73.7M	0.1%	47
2022 Q2	$114M	Buy	1,477,471 +871,872	+144%	+$66.4M	0.28%	42
2022 Q1	$44.2M	Buy	+605,599	New	+$40.7M	0.1%	45
2021 Q4	–	Sell	-17,071	Closed	-$1.01M	–	87
2021 Q3	$1.01M	Sell	17,071 -154	-0.9%	-$10.1K	﹤0.01%	59
2021 Q2	$1.15M	Buy	17,225 +6,856	+66%	+$447K	﹤0.01%	53
2021 Q1	$655K	Sell	10,369 -4,483,454	-100%	-$279M	﹤0.01%	55
2020 Q4	$279M	Buy	4,493,823 +3,783,133	+532%	+$233M	0.96%	36
2020 Q3	$42.8M	Sell	710,690 -3,044,997	-81%	-$183M	0.15%	52
2020 Q2	$221M	Buy	+3,755,687	New	+$225M	0.97%	34

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GQG Partners's BMY Position: Q2 2026 in Review

GQG Partners increased its Bristol-Myers Squibb (BMY) stake by 108% in Q2 2026, buying an estimated $2.87M and bringing the position to 96,264 shares worth $5.55M. The position accounts for 0.01% of the portfolio, ranked #76.

GQG Partners first reported a position in BMY in Q2 2020 and has held it in 16 quarters since. The position peaked at $733M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

GQG Partners held 96,264 shares of Bristol-Myers Squibb worth $5.55M as of Q2 2026.
GQG Partners bought 49,903 Bristol-Myers Squibb shares in Q2 2026, an estimated $2.87M.
Bristol-Myers Squibb made up 0.01% of GQG Partners's portfolio in Q2 2026, its #76 holding.
GQG Partners first reported a position in Bristol-Myers Squibb in Q2 2020 and has held it in 16 quarters since.
GQG Partners's Bristol-Myers Squibb position peaked at $733M in Q1 2025.
2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on GQG Partners's 13F filing for Q2 2026, filed 12 Aug 2026.